- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06295640
Relative Contribution of Brain Insulin Action for Postprandial Metabolism (BrainInsPPM)
The goal of this clinical trial is to clarify (i) the contribution of brain insulin action on regulation of systemic metabolism, (ii) sex-specific differences in the central regulation and (iii) the influence of the menstrual cycle in women.
Therefore, participants will undergo oral glucose tolerance tests combined with a double tracer dilution technique. This approach will be compared between days with insulin delivery to the brain as nasal spray and days with placebo spray.
Study Overview
Status
Conditions
Detailed Description
This research project aims to investigate to what extent brain insulin action is responsible for the control of postprandial metabolism compared to direct effects of insulin in peripheral target tissues. Furthermore, the study will investigate sex differences and the influence of the menstrual cycle on brain-derived coordination of postprandial signaling for metabolic control.
Therefore, insulin action in the brain will be introduced by application of insulin as nasal spray (on one day) versus carrier solution as placebo nasal spray (on another day) in a randomized, blinded fashion. Spray administration will be performed 15 minutes before a 75 gram oral glucose tolerance test that will introduce a postprandial state. On placebo day, the known spillover of tiny amounts of nasal insulin into the systemic circulation will be mimicked by an appropriate i.v. insulin bolus. This approach will be combined with a double-tracer dilution technique. Labeled glucose ([6,6-2H]glucose) will be infused 120 minutes before and during the OGTT (180 min) and will be used to address endogenous glucose production. The glucose drink from the OGTT will be enriched with [U-13C6]glucose to compute the glucose appearance rate (Ra). Basal endogenous glucose production will be calculated as well as post-load endogenous glucose production and rates of glucose disappearances (Rd). Using this approach, brain-derived regulation of postprandial metabolism including endogenous glucose production, glucose disappearance, insulin secretion, and secretion of proglucagon-cleavage products (incretins) will be examined.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Julia Hummel, Phd
- Phone Number: +4973150044744
- Email: julia.hummel@uniklinik-ulm.de
Study Contact Backup
- Name: Martin Heni, MD
- Phone Number: +4973150044505
- Email: martin.heni@uniklinik-ulm.de
Study Locations
-
-
-
Ulm, Germany, 89081
- Recruiting
- Universityhospital Ulm
-
Contact:
- Julia Hummel, Phd
- Phone Number: +4973150044744
- Email: julia.hummel@uniklinik-ulm.de
-
Contact:
- Rebecca Spies, MD
- Email: rebecca.spies@uniklinik-ulm.de
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- BMI < 24 kg/m2
- no known primary diseases
- no hormonal contraception
Exclusion Criteria:
- Alcohol or drug abuse
- Smoking
- At screening: Hb < 12 g/dl for women and Hb < 14 g/dl for men
- Any (clinical) condition that would endanger participant's safety or question scientific success according to a physician's opinion.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intranasal insulin spray
160 Units of human insulin as nasal spray
|
Subjects will undergo a 75 g OGTT (180 min) combined with a double tracer dilution.
The double-tracer dilution technique will be used to quantify endogenous glucose production, glucose appearance and disappearance rate.
[6,6-2H]glucose will be infused for a total of 300 minutes,while the infusion will start 120 minutes prior the OGTT and will last until the end of the OGTT.
Intranasal insulin will be administered 15 minutes prior to the start of the OGTT.
The drink consumed at time point 0 min contains 75 gram glucose, enriched with [U-13C6]-glucose.
|
Placebo Comparator: Placebo spray
Nasal spray containing placebo solution
|
Subjects will undergo a 75 g OGTT (180 min) combined with a double tracer dilution.
The double-tracer dilution technique will be used to quantify endogenous glucose production, glucose appearance and disappearance rate.
[6,6-2H]glucose will be infused for a total of 300 minutes,while the infusion will start 120 minutes prior the OGTT and will last until the end of the OGTT.
Placebo spray will be administered 15 minutes prior to the start of the OGTT.
The drink consumed at time point 0 min contains 75 gram glucose, enriched with [U-13C6]-glucose.
To mimic insulin spill-over from nasal spray into systemic circulation, an i.v.
insulin bolus of 3 mU × kg-1.
will be administered over ten minutes starting at time point -15 minutes on the placebo spray day.
On the insulin spray day a comparable amount of saline will be infused.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Endogenous glucose production
Time Frame: -120 minutes - 180 minutes during oral glucose tolerance test
|
Effect of intranasal insulin versus placebo on endogenous glucose production assessed with Steele's non-steady state model during an oral glucose tolerance test combined with double-tracer dilution technique.
|
-120 minutes - 180 minutes during oral glucose tolerance test
|
Rate of glucose disappearance
Time Frame: -120 minutes - 180 minutes during oral glucose tolerance test
|
Effect of intranasal insulin versus placebo on rate of glucose disappearance (Rd) assessed with Steele's non-steady state model during an oral glucose tolerance test combined with double-tracer dilution technique.
|
-120 minutes - 180 minutes during oral glucose tolerance test
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proglucagon cleavage products
Time Frame: 0-120 minutes during oral glucose tolerance test
|
Effect of intranasal insulin versus placebo on secretion of proglucagon cleavage products assessed by oral glucose tolerance test.
|
0-120 minutes during oral glucose tolerance test
|
Glucose tolerance
Time Frame: 0-120 minutes during oral glucose tolerance test
|
Effect of intranasal insulin versus placebo on glucose tolerance assessed as area under the glucose curve (0-120 minutes) and glucose levels at timepoint 120 minutes during the 75 g oral glucose tolerance test.
|
0-120 minutes during oral glucose tolerance test
|
Whole-body insulin sensitivity
Time Frame: 0-120 minutes during oral glucose tolerance test
|
Effect of intranasal insulin versus placebo on whole-body insulin sensitivity, assessed from glucose and insulin measurements during the 75 g OGTT.
|
0-120 minutes during oral glucose tolerance test
|
Insulin secretion
Time Frame: 0-180 minutes during oral glucose tolerance test
|
Effect of intranasal insulin versus placebo on insulin secretion assessed from glucose and insulin/C-peptide measurements during the 75 g oral glucose tolerance test.
|
0-180 minutes during oral glucose tolerance test
|
Post-absorptive energy expenditure
Time Frame: 30 minutes and 180 minutes during oral glucose tolerance test
|
Effect of intranasal insulin versus placebo on post-absorptive energy expenditure assessed by indirect calorimetry at timepoint 30 min and 180 min during an oral glucose tolerance test combined with double-tracer dilution technique.
|
30 minutes and 180 minutes during oral glucose tolerance test
|
Sex differences
Time Frame: -120 minutes - 180 minutes during oral glucose tolerance test
|
Explore sex differences in the brain-derived regulation of postprandial metabolism during the 75 g oral glucose tolerance tests.
Outcomes 1-7 will be compared between sexes.
|
-120 minutes - 180 minutes during oral glucose tolerance test
|
Menstrual cycle effects
Time Frame: -120 minutes - 180 minutes during oral glucose tolerance test
|
Differences between the follicular and the luteal phase of the menstrual cycle in the brain-derived regulation of postprandial metabolism during the 75 g oral glucose tolerance tests: Outcomes 1-7 will be compared between the phases of the menstrual cycle.
|
-120 minutes - 180 minutes during oral glucose tolerance test
|
Autonomic nervous system activity
Time Frame: -15 minutes - 180 minutes during oral glucose tolerance test
|
Effect of intranasal insulin versus placebo on autonomic nervous system activity assessed by heart rate variability using an 3-channel ECG at timepoint -15 min until 180 min during an oral glucose tolerance test combined with double-tracer dilution technique.
|
-15 minutes - 180 minutes during oral glucose tolerance test
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Martin Heni, MD, University of Ulm
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 300/2022
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glucose Metabolism Disorders
-
University of AberdeenCompletedMetabolism Disorder, GlucoseUnited Kingdom
-
Columbia UniversityCompletedMetabolism Disorder, GlucoseUnited States
-
University of LeipzigInstitut für Gesundheits- und Praxismanagement GmbHWithdrawn
-
Purdue UniversityAlmond Board of CaliforniaActive, not recruitingGlucose Intolerance | Glucose Metabolism Disorders (Including Diabetes Mellitus)United States
-
University of Missouri-ColumbiaCompletedGlucose | Blood Sugar; High | Glucose Metabolism Disorders (Including Diabetes Mellitus)United States
-
Solvay PharmaceuticalsTerminatedDyslipidemia | Glucose Metabolism DisorderPoland, Croatia, Finland, France, Germany, Netherlands, Romania, Ukraine
-
University of South CarolinaCompletedPhysical Activity | Sedentary Lifestyle | Metabolism Disorder, GlucoseUnited States
-
DLR German Aerospace CenterCompletedGlucose Metabolism Disorders | Local Glucose Uptake
-
Solvay PharmaceuticalsCompletedDyslipidemia/Glucose Metabolism DisorderPoland, Ukraine, United Kingdom
-
Solvay PharmaceuticalsCompletedDyslipidemia/Glucose Metabolism DisorderCzech Republic, France, Hungary, India, Lithuania, Poland, Slovakia
Clinical Trials on Oral glucose tolerance test with double-tracer dilution and intranasal insulin spray
-
Chiayi Christian HospitalCompletedGestational Diabetes MellitusTaiwan
-
University of PennsylvaniaActive, not recruiting
-
University of Texas Southwestern Medical CenterWithdrawnCystic Fibrosis Related DiabetesUnited States
-
Vanderbilt-Ingram Cancer CenterRecruitingDiabetes Mellitus | CancerUnited States
-
Hvidovre University HospitalUniversity of CopenhagenCompletedObesity, Morbid | Type2 DiabetesDenmark
-
University Hospital, LilleNot yet recruitingType2 Diabetes | Impaired Glucose Tolerance
-
Yale UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedT2D | IGT - Impaired Glucose ToleranceUnited States
-
Liverpool Heart and Chest Hospital NHS Foundation...Completed
-
Columbia UniversityCompletedInsulin Resistance | Dyslipidemias | HyperinsulinemiaUnited States